Hopp til innhold
Visinnovasjon.no > Aktuelt > Investing millions on cancer drug from Bergen
VIS logo Logo for VIS

Investing millions on cancer drug from Bergen

BerGenBio has raised 75 mNOK in capital through an issue of shares towards internal and external investors.
05.02.2014

– It’s flattering to see that they believe in us, says Richard Godfrey, CEO of BerGenBio AS, to Bergens Tidende.

Among the investors is Norsk Innovasjonskapital II, a fund established by BTO in cooperation with Televenture.

BerGenBio was established in 2007 by BTO, Unifob AS and researchers from The Department of Biomedicine at UiB.

Read more in Bergens Tidende; «Satser millioner på kreftmedisin fra Bergen» (In Norwegian)

ekspander_ikon_20x20_svartekspander_ikon_20x20fb_28x28footer_vislogo_167x85hopptil-pilinsta_28x28kvitpil_ikon_19x13linkedin_28x28logo_toppmeny_vis_logo_59x50nfr_merke_250x103nonameraudpil_ikon_19x13siva-partner_hoover_291x48siva-partner_liggende_291x48twitter_28x28